These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16234894)

  • 21. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
    Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies.
    Siddiqui A; Kowey PR
    Curr Opin Cardiol; 2006 Sep; 21(5):517-25. PubMed ID: 16900017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implantable cardioverter-defibrillator therapy in clinical practice.
    Cesario DA; Dec GW
    J Am Coll Cardiol; 2006 Apr; 47(8):1507-17. PubMed ID: 16630984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z; Rogers JG
    Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chronic heart failure and sudden death: the message of CIBIS-III].
    Dequarti MC; Poggio L; Vanoli E
    Recenti Prog Med; 2007 Dec; 98(12):638-45. PubMed ID: 18369041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
    Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B; Fonarow GC; Gheorghiade M; Deedwania PC; Duprez DA
    Am J Cardiol; 2006 May; 97(10A):26F-33F. PubMed ID: 16698332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Congestive heart failure: new paradigms and therapeutic targets.
    Arnaout MS; Alam SE
    J Med Liban; 2003; 51(3):169-75. PubMed ID: 15707079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative management of chronic heart failure.
    Groban L; Butterworth J
    Anesth Analg; 2006 Sep; 103(3):557-75. PubMed ID: 16931661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing mortality with device therapy in heart failure patients without ventricular arrhythmias.
    Chapa DW; Lee HJ; Kao CW; Friedmann E; Thomas SA; Anderson J; Bardy GH
    Am J Crit Care; 2008 Sep; 17(5):443-52; quiz 453. PubMed ID: 18776000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence-based drug treatment of heart failure.
    Wasson S; Fleming D; Reddy HK
    Mo Med; 2005; 102(6):540-8; quiz 548-9. PubMed ID: 16355640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial.
    Acker MA; Bolling S; Shemin R; Kirklin J; Oh JK; Mann DL; Jessup M; Sabbah HN; Starling RC; Kubo SH;
    J Thorac Cardiovasc Surg; 2006 Sep; 132(3):568-77, 577.e1-4. PubMed ID: 16935112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implantable defibrillators and beta-blockers in patients with left ventricular dysfunction: economic, ethical, and legal considerations.
    Silver MT
    Am Heart J; 2007 Apr; 153(4 Suppl):59-64. PubMed ID: 17394904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State-of-the-art implantable cardiac assist device therapy for heart failure: bridge to transplant and destination therapy.
    Park SJ; Kushwaha SS; McGregor CG
    Clin Pharmacol Ther; 2012 Jan; 91(1):94-100. PubMed ID: 22113236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Heart failure--epidemic of the 21st century].
    Hradec J
    Vnitr Lek; 2004 Oct; 50 Suppl 1():S23-31. PubMed ID: 15651139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.